To view this email as a web page, click here.

Age Disparities Spell Trouble for Industry-Funded Oncology Trials

A study published in JAMA reveals that age disparities between oncology trial participants are common and even increasing, despite opposition.

FDA Approves Apalutamide for Prostate Cancer

Apalutamide was initially approved in 2018 for patients with non-metastatic castration-resistant prostate cancer; the recent approval is for patients with metastatic castration-sensitive prostate cancer.

IN CASE YOU MISSED IT

Project Orbis Enables First International Approval in U.S., Canada, Australia

The first-of-its-kind collaboration led to the approval of a combination therapy for patients with endometrial cancer.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.